Contact SRI Biosciences

Infectious Disease

SRI is a leader in performing antimicrobial assays with novel agents. These agents are tested against clinically important microorganisms exhibiting either a single- or multiple- antibiotic resistance pattern. We also offer discovery services in lead compound discovery and optimization, in vitro and in vivo model development, mechanisms of action elucidation, and cost-effective synthesis development.

SRI is the world's leading provider of preclinical development services for anti-infective therapeutics and vaccines. We currently hold the contracts with the National Institute of Allergy and Infectious Diseases (NIAID) for preclinical safety, pharmacokinetics and clinical manufacturing of anti-infectives, and safety, immunogenicity, and IND preparation for HIV vaccines, making SRI the largest government program for the development of anti-infectives. We are also working with the National Cancer Institute (NCI) and numerous private biotechnology companies on the development of vaccines and anti-infective therapeutics.

We can meet all of your preclinical needs from lead identification to Phase I clinical trials in time-frames that are well below industry-averages.

Examples of some of our recent anti-infective therapeutic and vaccine development programs:

• Toxicity and pharmacokinetics of Apollon APL400-01 HIV vaccine
• Preclinical testing of the anti-malarial AQ-13
• Chronic toxicity testing of rVB-7 vaccine
• Testing of vaginal microbicides for vaginal irritation and uptake
• Preclinical safety, immunogenicity and IND preparation of HIV vaccines

To learn more about our research and the services we offer, visit the following links:

Medicinal Chemistry and Custom Synthesis
In Vitro Assay Development
Comprehensive Drug Development

Contact SRI Biosciences

       Last Updated Jan 25, 2010